| Per-and polyfluoroalkyl substances in sera from children 3 to 11 years of age participating in the National Health and Nutrition Examination Survey 2013–2014 X Ye, K Kato, LY Wong, T Jia, A Kalathil, J Latremouille, AM Calafat International journal of hygiene and environmental health 221 (1), 9-16, 2018 | 119 | 2018 |
| Per-and polyfluoroalkyl substances and fluorinated alternatives in urine and serum by on-line solid phase extraction–liquid chromatography–tandem mass spectrometry K Kato, AA Kalathil, AM Patel, X Ye, AM Calafat Chemosphere 209, 338-345, 2018 | 118 | 2018 |
| Brain-accumulating nanoparticles for assisting astrocytes to reduce human immunodeficiency virus and drug abuse-induced neuroinflammation and oxidative stress B Surnar, AS Shah, M Park, AA Kalathil, MZ Kamran, R Ramirez Jaime, ... ACS nano 15 (10), 15741-15753, 2021 | 36 | 2021 |
| New formulation of old aspirin for better delivery AA Kalathil, A Kumar, B Banik, TA Ruiter, RK Pathak, S Dhar Chemical Communications 52 (1), 140-143, 2016 | 30 | 2016 |
| Controlled release nanoplatforms for three commonly used chemotherapeutics J Costoya, B Surnar, AA Kalathil, N Kolishetti, S Dhar Molecular aspects of medicine 83, 101043, 2022 | 23 | 2022 |
| New pathway for cisplatin prodrug to utilize metabolic substrate preference to overcome cancer intrinsic resistance AA Kalathil, S Guin, A Ashokan, U Basu, B Surnar, KS Delma, LM Lima, ... ACS Central Science 9 (7), 1297-1312, 2023 | 18 | 2023 |
| Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites A Ashokan, S Sarkar, MZ Kamran, B Surnar, AA Kalathil, A Spencer, ... Proceedings of the National Academy of Sciences 121 (20), e2318119121, 2024 | 7 | 2024 |
| Distribution of per-and polyfluoroalkyl substances in human urine and serum K Kato, AA Kalathil, AM Calafat, XS Ye Drug Metabolism and Pharmacokinetics 33 (1), S62, 2018 | 2 | 2018 |
| Modification of drugs for incorporation into nanoparticles AA Kalathil, B Banik, A Kumar, S Dhar US Patent App. 15/280,010, 2017 | 2 | 2017 |
| Correction to “Brain-Accumulating Nanoparticles for Assisting Astrocytes to Reduce Human Immunodeficiency Virus and Drug Abuse-Induced Neuroinflammation and Oxidative Stress” B Surnar, AS Shah, M Park, AA Kalathil, MZ Kamran, R Ramirez Jaime, ... ACS nano 18 (33), 22608-22608, 2024 | | 2024 |
| Correction to “New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance” AA Kalathil, S Guin, A Ashokan, U Basu, B Surnar, KS Delma, LM Lima, ... ACS Central Science 9 (8), 1705-1705, 2023 | | 2023 |
| Correction to “New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance” S Dhar, AA Kalathil, S Guin, A Ashokan, U Basu, B Surnar, KS Delma, ... ACS Central Science 9 (8), , 1705, 2023 | | 2023 |
| Delivery of cardiolipin to the mitochondria for Barth syndrome MZ Kamran, AA Kalathil, S Dhar ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 257, 2019 | | 2019 |
| Series of cisplatin prodrugs to inhibit fatty acid oxidation in prostate cancer A Kalathil, S Dhar ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018 | | 2018 |
| Temporal Trends in Exposure to C4-C8 Perfluoroalkyl Substances among US Adults X Ye*, K Kato, J Ma, A Kalathil, L Jia, A Calafat ISEE Conference Abstracts 28 2016 (1), P3-386, 2016 | | 2016 |
| Hydrophobic aspirin analogues for better delivery T Ruiter, A Kumar, B Banik, A Kalathil, S Dhar ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 251, 2016 | | 2016 |
| Treatment of Lipid Dysregulation in Diseases Through Orally Administrable Nanoparticle Mediated Treatment AA Kalathil University of Miami, 0 | | |
